A CAR-T cell therapy for advanced B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests an experimental treatment called CT120 (a CAR-T cell therapy) for people with certain types of B-cell lymphoma that have returned or not responded to treatment. CAR-T therapy uses your own immune cells, modified in a lab, to target and destroy cancer cells, and this trial aims to see if it is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You need a confirmed diagnosis of a type of B-cell lymphoma, such as diffuse large B-cell lymphoma or certain follicular lymphomas.
- Your lymphoma must have come back or not responded to at least two previous treatments, or you had a stem cell transplant using your own cells, or you didn't improve after two cycles of initial therapy.
- You must have at least one measurable tumor of a certain size.
- You need to be in generally good health, with adequate organ function and a life expectancy of at least 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy called CT1194D for people with certain B-cell blood cancers that have not responded to or have come back after standard treatment. The therapy is designed to find and destroy cancer cells that carry the CD19 or CD20 marker.
This trial tests a personalized treatment using your own immune cells (called CAR-T cells) that are modified in a lab to target and kill lymphoma cells. It is for people with a type of B-cell non-Hodgkin lymphoma that has come back or not improved after standard treatments.
This trial tests a new CAR-T cell treatment for people with B-cell lymphoma that has come back or not responded to standard treatments. CAR-T cells are specially engineered immune cells that target and kill lymphoma cells. The study aims to see if this treatment is safe and effective.
This trial tests a new CAR-T treatment that targets three proteins on lymphoma cells (CD19, CD22, and BCMA). It is for people with certain types of B-cell lymphoma that have come back or are not responding to standard treatments.
This trial tests a new type of CAR-T cell therapy designed to be stronger against B-cell lymphoma that has come back or not responded to previous treatments. The treatment uses your own immune cells, which are modified in a lab to better attack cancer cells.
This early-stage study tests a new type of immune cell therapy (CAR-T) that targets two proteins, CD19 and CD20, on your lymphoma cells. It is for people with aggressive B-cell lymphoma that has returned or not responded after several treatments. The goal is to see if this therapy can help shrink the cancer.
Hear when a new B-cell Non-Hodgkin's Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.